These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15258905)

  • 1. Differential control of apoptosis by DJ-1 in prostate benign and cancer cells.
    Hod Y
    J Cell Biochem; 2004 Aug; 92(6):1221-33. PubMed ID: 15258905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
    Perego P; Ciusani E; Gatti L; Carenini N; Corna E; Zunino F
    Biochem Pharmacol; 2006 Mar; 71(6):791-8. PubMed ID: 16438941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
    Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
    Griffith TS; Kemp TJ
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):175-84. PubMed ID: 12811515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptotic responsiveness of PC-3 prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand: evidence for differential effects of Bcl-xL and Bcl-2 down-regulation.
    Sonnemann J; Gekeler V; Sagrauske A; Müller C; Hofmann HP; Beck JF
    Int J Oncol; 2004 Oct; 25(4):1171-81. PubMed ID: 15375570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.
    Zhang X; Jin TG; Yang H; DeWolf WC; Khosravi-Far R; Olumi AF
    Cancer Res; 2004 Oct; 64(19):7086-91. PubMed ID: 15466204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
    Kang J; Bu J; Hao Y; Chen F
    Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
    Shankar S; Singh TR; Srivastava RK
    Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
    Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
    Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R
    J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis.
    Yamaguchi K; Uzzo RG; Pimkina J; Makhov P; Golovine K; Crispen P; Kolenko VM
    Oncogene; 2005 Sep; 24(38):5868-77. PubMed ID: 15897871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis.
    Sanlioglu AD; Koksal IT; Karacay B; Baykara M; Luleci G; Sanlioglu S
    Cancer Gene Ther; 2006 Jan; 13(1):21-31. PubMed ID: 16052230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
    Yoo J; Lee YJ
    Mol Pharmacol; 2007 Dec; 72(6):1586-92. PubMed ID: 17848598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kazhdan I; Marciniak RA
    Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
    Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
    Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
    Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
    Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.
    Yasuda T; Yoshida T; Goda AE; Horinaka M; Yano K; Shiraishi T; Wakada M; Mizutani Y; Miki T; Sakai T
    Mol Cancer Res; 2008 Dec; 6(12):1852-60. PubMed ID: 19074830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.